What is the value of 'me-too' drugs?

Health Care Management Science

Volumn 16, Issue 4, 2013, Pages 300-313

  Régnier, Stephane ^a,b  

^a UNIVERSITY OF NEUCHÂTEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cost savings; First mover advantage; Follow on drugs; Peak share; Share of voice

Indexed keywords

EID: 84887401614     PISSN: 13869620     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10729-013-9225-3     Document Type: Article

References (35)

1. US Food and Drug Administration (2009) NDA approvals by therapeutic potential and chemical type. Available from URL: http://www. fda. gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAApprovalsbyTherapeuticPotentialandChemicalType/default. htm. Accessed 14 December 2011.
2. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2): 151-185.
3. Berenson A (14 November 2005) Big drug makers see sales decline with their image. New York Times. Available from URL: http://www. nytimes. com/2005/11/14/business/14pharma. html.
4. Hollis A (13 December 2004) Me-too drugs: is there a problem? Submission to the WHO Commission on Intellectual Property and Public Health. Available from URL: http://www. who. int/intellectualproperty/topics/ip/Me-tooDrugs_Hollis1. pdf.
5. US Congress Office of Technology Assessment (1993) Pharmaceutical R&D: costs, risks and rewards. Available from URL: http://www. fas. org/ota/reports/9336. pdf.
6. Stange KC (2007) Time to ban direct-to-consumer prescription drug marketing. Ann Fam Med 5(2): 101-104.
7. Aitken M, Berndt ER, Cutler DM (2009) Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood) 28(1): w151-w160.
8. Morgan SG, Bassett KL, Wright JM, Evans RG, Barer ML, Caetano PA, Black CD (2005) "Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. BMJ 331: 815-816.
9. Angell M (2004) The truth about the drug companies: how they deceive us and what to do about it. Random House, New York.
10. Azoulay P (2002) Do pharmaceutical sales respond to scientific evidence? J Econ Manag Strateg 11(4): 551-594.
11. Simon G (2001) Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA 286(23): 3003-3004.
12. Lu ZJ, Comanor WS (1998) Strategic pricing of new pharmaceuticals. Rev Econ Stat 80(1): 108-118.
13. Lexchin J (2006) Do manufacturers of brand-name drugs engage in price competition? An analysis of introductory prices. CMAJ 174(8): 1120-1121.
14. Health Strategies Group (2010) Best practices in health plan marketing. Category management and review no. 1: Asthma agents. Health Strategies Group, Lambertville.
15. DiMasi JA, Paquette C (2004) The economics of follow-on drug research and development: trends in entry rates and the timing of development. PharmacoEconomics 22(2 Suppl 2): 1-14.
16. Huskamp HA (2006) Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value. Health Aff (Millwood) 25(3): 635-646.
17. Kalyanaram G, Urban GL (1992) Dynamic effects of order-of-entry on market share, trial penetration, and repeat purchases for frequently purchased consumer goods. Mark Sci 11(3): 235-250.
18. Robinson WT, Fornell C (1985) Sources of market pioneer advantages in consumer goods industries. J Mark Res 22(3): 305-317.
19. Fischer M, Leeflang PSH, Verhoef PC (2010) Drivers of peak sales for pharmaceutical brands. Quant Mark Econ 8: 429-460.
20. Prins R, Verhoef PC (2007) Marketing communication drivers of adoption timing of a new EService among existing customers. J Mark 71(2): 169-183.
21. Fischer M, Albers S (2010) Patient- or physician-oriented marketing: what drives primary demand for prescription drugs? J Mark Res 47(1): 103-121.
22. Haute Autorité de la Santé (2009) Commission de la transparence: les avis sur les médicaments. Available from URL: http://www. has-sante. fr/portail/jcms/c_5268/medicaments?cid=c_5268. Accessed 14 December 2011.
23. IMS Health (2009) Available from URL: http://www. imshealth. com/portal/site/ims. Accessed December 2009.
24. SDI Health (2009) Available from URL: http://www. sdihealth. com/. Accessed December 2009.
25. First DataBank (2009) AnalySource Online. http://www. firstdatabank. com/Products/analysource. aspx. Accessed 14 December 2011.
26. US Food and Drug Administration. NME drug and new biologic approvals. Available from URL: http://www. fda. gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/ucm121136. htm. Accessed 14 December 2012.
27. Lebas M, Certain BM (1992) Médicalisation du remboursement: une solution à la maîtrise des dépenses de santé? J econ med 10(7-8): 451-470.
28. Corstjens M, Demeire E, Horowitz I (2005) New product success in the pharmaceutical industry: how many bites at the cherry? Econ Innov New Technol 14(4): 319-331.
29. Lichtenberg FR, Duflos G (2009) The effect of patent expiration on U. S. drug prices, marketing, and utilization by the public. Center for Medical Progress at the Manhattan Institute. Available from URL: http://www. manhattan-institute. org/html/mpr_11. htm. Accessed 10 February 2013.
30. Greuel JM (2008) Pharma and biotech: is it possible to keep growing? Pharma Focus Asia (Issue 6): 6-9.
31. Walters D (2002) Operations strategy. Palgrave Macmillan, Basingstoke.
32. Kaufman M (1 July, 2005) FDA was told of Viagra-blindness link months ago. Washington Post. Available from URL: http://pqasb. pqarchiver. com/washingtonpost/access/861469911. html?FMT=ABS&FMTS=ABS: FT&date=Jul+1%2C+2005&author=Marc+Kaufman&pub=The+Washington+Post&edition=&startpage=A. 02.
33. Katz DM (28 October 2005) Drug discount peddlers. CFO. com. Available from URL: http://www. cfo. com/printable/article. cfm/5079733. Accessed 14 December 2011.
34. Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG (2004) Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 42(12): 1176-1185.
35. Kravitz RL, Epstein RM, Feldman MD et al (2005) Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 293(16): 1995-2002.